H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on PDS Biotechnology (PDSB) to $13 from $21 and keeps a Buy rating on the shares following the Q4 report. The firm adjusted timelines for the company’s potential product launches based on the timing of the recently initiated VERSATIL-003 study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDSB:
- Options Volatility and Implied Earnings Moves Today, March 27, 2025
- PDS Biotechnology reports FY24 EPS ($1.03), consensus ($1.11)
- PDSB Earnings this Week: How Will it Perform?
- PDS Biotech announces FDA clearance of IND apprlication for Versamune MUC1 combo
- Biotech Alert: Searches spiking for these stocks today